"In an interview with Targeted Therapies in Oncology, C. Ola Landgren, MD, PhD, discussed how the availability of daratumumab by subcutaneous administration will affect clinical practice going forward".
https://www.targetedonc.com/view/ease-of-use-with-subcutaneous-daratumumab-supplants-the-intravenous-formulation-as-standard-of
https://www.targetedonc.com/view/ease-of-use-with-subcutaneous-daratumumab-supplants-the-intravenous-formulation-as-standard-of
